Angela Plette
Papers
1
Total Citations
4
H-Index
1
About
Angela Plette is a clinical researcher whose work focuses on advancing treatment strategies for high-risk prostate cancer, particularly through neoadjuvant chemotherapy approaches. Her most notable contribution is the phase I/II clinical trial investigating neoadjuvant weekly ixabepilone for high-risk prostate cancer, published in 2012. This study addressed critical gaps in the field, exploring whether ixabepilone—a novel chemotherapeutic agent—could achieve tumor downstaging and treat micrometastatic disease without the operative morbidity seen with prior docetaxel regimens. While the paper has accumulated 4 citations, its significance lies in its pioneering effort to identify safer, more effective neoadjuvant options for patients with aggressive disease. Plette’s work underscores the challenges and potential of translating promising preclinical findings into clinical practice, contributing to the broader dialogue on optimizing perioperative therapy. Her research remains relevant for oncologists and urologists seeking to improve outcomes in high-risk prostate cancer, highlighting the ongoing need for innovative clinical trials in this space.
Research Focus
Key Achievements
Top Papers
- 1